# US 2004/0072722 A1 · Methods for assessing efficacy of chemotherapeutic agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072722 A1
- Document ID: US20040072722A1
- Status: Published application
- Kind: A1
- Application number: 10/336,659
- Filed: 2003-01-02
- Published: 2004-04-15
- Earliest claimed: 2002-10-10
- Inventors: Paul L. Kornblith; Sean McDonald
- Web page: https://patentgrep.com/patent/US20040072722A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods are provided for accurately predicting efficacy of chemotherapeutic agents. Methods of the invention increase the positive predictive value of chemosensitivity assays by assessing both the ability of a chemotherapeutic to destroy cells and the genetic propensity of those cells for resistance. Results obtained using methods of the invention provide insight into the in vivo effectiveness of a therapeutic, and lead to more effective chemotherapeutic treatment.

## Claims

### Claim 1

A method for assessing efficacy of a chemotherapeutic agent, the method comprising:
conducting an assay to determine whether a chemotherapeutic agent affects cellular phenotype of a sample of tumor cells obtained from a patient;
determining whether said patient comprises a genetic characteristic associated with resistance to said chemotherapeutic agent; and
assessing efficacy of said chemotherapeutic agent based upon results of said conducting and detecting steps.

### Claim 2 (depends on 1)

The method of claim 1, wherein said sample of cells in said conducting step comprise malignant cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein said sample of cells in said conducting step comprise abnormal proliferating cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein said cellular phenotype is cell growth rate or death.

### Claim 5 (depends on 1)

The method of claim 1, wherein said genotypic change is a genetic polymorphism or mutation.

### Claim 6 (depends on 1)

The method of claim 1, wherein said determining step comprises sequencing a portion of the genome of cells from said patient

### Claim 7 (depends on 6)

The method of claim 6, wherein said sequencing is conducted through hybridization or restriction sequencing techniques.

### Claim 8 (depends on 1)

The method of claim 1, wherein said determining step comprises comparing said genotype characteristic to a database of genotype characteristics associated with resistance to or altered disposition of said chemotherapeutic agent.

### Claim 9

A method for selecting a chemotherapeutic agent for treating a patient, the method comprising:
conducting an assay to determine whether a chemotherapeutic agent effects cellular phenotype of a sample of cells from a patient;
determining whether cells from said patient comprise a genotypic characteristic associated with resistance to said chemotherapeutic; and
selecting said chemotherapeutic agent for treating said patient if said chemotherapeutic agent effects cellular phenotype of said sample of cells in said conducting step and if said cells in said determining step do not comprise a genotypic characteristic associated with resistance to said chemotherapeutic agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein said sample of cells in said conducting step comprise malignant cells.

### Claim 11 (depends on 9)

The method of claim 9, wherein said sample of cells in said conducting step comprise abnormal proliferating cells.

### Claim 12 (depends on 9)

The method of claim 9, wherein said cellular phenotype is cell growth rate or death.

### Claim 13 (depends on 9)

The method of claim 9, wherein said genotypic change is a genetic polymorphism or mutation.

### Claim 14 (depends on 9)

The method of claim 9, wherein said determining step comprises sequencing a portion of the genome of cells from said patient

### Claim 15 (depends on 14)

The method of claim 14, wherein said sequencing is accomplished through hybridization or restriction sequencing techniques.

### Claim 16 (depends on 9)

The method of claim 9, wherein said determining step comprises comparing said genotype characteristics to a database of genotype characteristics associated with resistance to or altered disposition of said chemotherapeutic agent.

### Claim 17

A method for assessing efficacy of a chemotherapeutic agent on malignant cells in a patient, the method comprising:
exposing malignant cells from a patient to a chemotherapeutic agent;
conducting an assay to determine whether said chemotherapeutic agent effects cellular phenotype of said malignant cells from said patient;
determining whether a sample of cells from said patient comprise a genotypic characteristic associated with resistance to said chemotherapeutic agent; and
assessing efficacy of said chemotherapeutic agent on said malignant cells from said patient based upon results of said conducting and detecting steps.

### Claim 18 (depends on 17)

The method of claim 17, further comprising:
selecting said chemotherapeutic agent for treating said patient if said chemotherapeutic agent effects cellular phenotype of said malignant cells in said conducting step and if said cells in said determining step do not comprise a genotypic characteristic associated with resistance to said chemotherapeutic agent.

### Claim 19 (depends on 17)

The method of claim 17, wherein said malignant cells are obtained from a tumor specimen from said patient.

### Claim 20 (depends on 17)

The method of claim 17, wherein said cells in said determining step are obtained from a blood sample from said patient.

### Claim 21 (depends on 17)

The method of claim 17, wherein said cells in said determining step are obtained from a buccal smear from said patient.

### Claim 22 (depends on 17)

The method of claim 17, wherein said cellular phenotype is cell growth rate or death.

### Claim 23 (depends on 17)

The method of claim 17, wherein said genotypic change is a genetic polymorphism or mutation.

### Claim 24 (depends on 17)

The method of claim 17, wherein said determining step comprises sequencing a portion of the genome of cells from said patient

### Claim 25 (depends on 24)

The method of claim 24, wherein said sequencing is accomplished through hybridization or restriction sequencing techniques.

### Claim 26 (depends on 17)

The method of claim 17, wherein said determining step comprises comparing said genotype characteristics to a database of genotype characteristics associated with resistance to or altered disposition of said chemotherapeutic agent.
